Penny Stock which provides a wide range of products and services related to agrochemicals, gained marginally in the day’s trade after it received an order worth Rs. 1 Crore from 5 different clients.
In the day’s trade on November 24, 2023, the shares of Aristo Bio-Tech and Lifescience Limited closed at Rs. 75.90, down 0.13 percent from its previous day’s close price of Rs. 76 and its market capitalization is Rs. 51.67 Crores.
As per the company’s filing on NSE, Aristo Bio-Tech and Lifescience Limited have received new purchase orders worth ~Rs. 1.04 Crore from 5 clients for the supply of various agrochemicals on Freight-Ex-Works Basis. The work order is to be executed at the earliest within 15 days. The said receipt Order would enhance the customer base and attribute towards the Company’s profitability.
The company’s revenue grew 31.36 percent from Rs. 165.76 Crores in FY22 to Rs. 217.75 Crores in FY23, accompanied by increasing profits of Rs. 1.43 Crore to Rs. 3.56 Crore.
It has reported a return on equity (ROE) of 15.82 percent and a return on capital employed (ROCE) of 16.11 percent, it is making good returns on its equity and capital employed.
Aristo Biotech and Lifescience is an agrochemical company, it is engaged in providing, manufacturing, formulation, supply, and packaging work services for various pesticides like insecticides, fungicides, herbicides, plant growth regulators, and a wide variety of other Agrochemicals in India as well as for export.
Note: Due to the illiquidity in penny stocks, the stock can hit its assigned circuit levels with just a minor increase in volume of trades. Even if the stock prices are within the usual buying range for the investors and offer enormous potential profits, penny stocks are quite dangerous for retail investors.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
